Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5840757 | BAXTER HLTHCARE CORP | Lipid emulsion intended for parenteral or enteral feeding |
Nov, 2015
(8 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 03, 2016 |
Drugs and Companies using OLIVE OIL; SOYBEAN OIL ingredient
Market Authorisation Date: 03 October, 2013
Treatment: NA
Dosage: EMULSION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11173189 | BAXTER HLTHCARE CORP | Daptomycin formulations containing a combination of sorbitol and mannitol |
Mar, 2041
(16 years from now) |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 25 January, 2022
Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10583155 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US11510942 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10905713 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10653719 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10912795 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10478453 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10905714 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10918662 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US10933089 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
US11510941 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Mar, 2039
(14 years from now) | |
US10543186 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) | |
US10493051 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) | |
US10702490 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) | |
US11045438 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(14 years from now) |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need ther...
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6207661 | BAXTER HLTHCARE CORP | Premixed formulation of piperacillin sodium and tazobactam sodium injection |
Feb, 2019
(5 years ago) | |
US6900184 | BAXTER HLTHCARE CORP | Compositions containing pipercillin and tazobactam useful for injection |
Apr, 2023
(1 year, 13 days ago) | |
US8133883 | BAXTER HLTHCARE CORP | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(1 year, 13 days ago) | |
US7915229 | BAXTER HLTHCARE CORP | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(1 year, 13 days ago) |
Drugs and Companies using PIPERACILLIN SODIUM; TAZOBACTAM SODIUM ingredient
Market Authorisation Date: 24 February, 1998
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE;INJECTION